Safety and tolerability of a bevacizumab biosimilar (Effivia®) in adult Mexican patients with cancer: a multicenter, observational, prospective clinical study
IntroductionSafety of biosimilars is of major relevance for patients and medical community. The aim of this study was to evaluate the safety and tolerability of a bevacizumab biosimilar alongside standard chemotherapy in adult patients with cancer. In addition, the impact on patients’ quality-of-lif...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Frontiers Media S.A.
2025-05-01
|
| Edice: | Frontiers in Drug Discovery |
| Témata: | |
| On-line přístup: | https://www.frontiersin.org/articles/10.3389/fddsv.2025.1591991/full |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|